CD19 and lymphoma: Interestingly, MYC expression is reported to promote CD19 expression and vice versa in lymphoma xenografts (15), and further analysis of outcomes following treatment with CD19-directed therapies in patients with R/R MYC-rearranged LBCL could be explored to understand if these are of particular benefit to this population.